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Abstract
Background: Purchasers can play an important role in eliminating racial and ethnic disparities in health care. A
need exists to develop a compelling “business case” from the employer perspective to put, and keep, the issue of
racial/ethnic disparities in health care on the quality improvement agenda for health plans and providers.
Methods: To illustrate a method for calculating an employer business case for disparity reduction and to compare
the business case in two clinical areas, we conducted analyses of the direct (medical care costs paid by employers)
and indirect (absenteeism, productivity) effects of eliminating known racial/ethnic disparities in mammography
screening and appropriate medication use for patients with asthma. We used Markov simulation models to
estimate the consequences, for defined populations of African-American employees or health plan members, of a
10% increase in HEDIS mammography rates or a 10% increase in appropriate medication use among either adults
or children/adolescents with asthma.
Results: The savings per employed African-American woman aged 50-65 associated with a 10% increase in HEDIS
mammography rate, from direct medical expenses and indirect costs (absenteeism, productivity) combined, was
$50. The findings for asthma were more favorable from an employer point of view at approximately $1,660 per
person if raising medication adherence rates in African-American employees or dependents by 10%.
Conclusions: For the employer business case, both clinical scenarios modeled showed positive results. There is a
greater potential financial gain related to eliminating a disparity in asthma medications than there is for eliminating
a disparity in mammography rates.
Background
Disparities in health among racial and ethnic groups in
the US are well documented [1]. Although important
exceptions can be found, a general pattern of poorer
health (e.g., life expectancy, self-reported health status,
incidence of disease) exists among members of racial or
ethnic minority groups. One contributing factor to dis-
parities in health is disparities in quality of health care;
a similarly extensive literature documents disparities
among racial and ethnic groups in terms of access to
care and quality of care received [2,3]. Disparities in
quality refer to differences in levels of quality (based on
defined measurable indicators) that have no clinical
justification for members of different racial/ethnic
groups [4].
Some disparities in health and health care reflect the
combined effects of poverty and lack of health insurance
[5]. Evidence of disparities in quality of care exists
among employed and insured individuals, even among
individuals in a single type of insurance or a single
health plan [6-8]. Demonstration projects supported by
the Commonwealth Fund and the Health Resources and
Services Administration (HRSA) have shown that data
on enrollees’ race/ethnicity can be linked to health plan
quality of care data to generate reports that identify dis-
parities in quality of care at the individual health plan
level [9-11].
Purchasers can play an important role in eliminating
disparities by requiring health plans to analyze quality of
care data separately by race/ethnicity and provide
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regular reports; and by using a variety of mechanisms
inherent in the purchaser-supplier relationship (e.g.,
incentive payment systems) to focus attention on the
disparity problem and change clinical practice [12,13].
Thus a need exists to develop a compelling “business
case” from the employer perspective to put, and keep,
the issue of racial/ethnic disparities in health care on
the radar screen [14]. A “business case” from the
employer perspective inevitably will be somewhat differ-
ent from one created from the health plan or provider
perspective. Reductions in direct health care expendi-
tures that follow from improved quality of care may or
may not be relevant, for example, depending on whether
the employer or a health plan is the at-risk entity in any
specific time period.
In principle, the several components to a “business
case for disparity reduction” from the employer perspec-
tive include, but are not necessarily limited to:
• additional direct medical expenses attributable to
disparities in quality of care;
• costs of absenteeism, or lack of productivity while
at work (sometimes called “presenteeism”) related to
poor health status that follows from health care
disparities;
• costs of absenteeism or diminished productivity
related to receiving medical care for preventable
conditions or complications;
• costs of absenteeism or diminished productivity
related to employees’ obligations as caregivers for
children or other family members (e.g., mother or
father has to take day off from work when child
with asthma has an exacerbation);
• costs of training or hiring new staff when employ-
ees are disabled, retired, or die;
• costs of specific interventions or general system
changes designed to reduce or eliminate disparities;
• potential additional costs of medical care as a
result of eliminating disparities (e.g., additional costs
of antidepressant medications among minority
patients who were previously under-treated).
The elements of a business case for disparity reduc-
tion are similar to, perhaps even identical to, the ele-
ments of a business case for quality improvement. In
both domains, the activities in question include data col-
lection and analysis, identification of processes or out-
comes in which quality is less than an ideal or target
level, interventions of various types to improve quality,
and additional cycles of data collection and analysis to
determine whether quality has improved. Most of this
work lies outside the usual routine of medical care for
which payment is provided, so additional costs are
incurred for which some sort of business case is
required.
We illustrate both a method for calculating an
employer business case for disparity reduction and a
comparison of the business case in two clinical areas.
We conducted analyses of the direct (medical care costs
paid by employers) and indirect (absenteeism, productiv-
ity) effects of eliminating known racial/ethnic disparities
in mammography screening and appropriate medication
use for patients with asthma. We chose these two clini-
cal domains because they represent areas in which dis-
parities in specific quality of care measures have been
documented and because a body of published data exist
linking disparities in quality of care to medical care
costs and data on absenteeism and productivity. We
aimed to determine whether a positive business case
exists for disparity reduction in either clinical case sce-
nario in an effort to emphasize the importance for
employers’ ongoing participation in disparity reduction
efforts.
Clinical Settings for Employer Business Case Modeling
Breast Cancer
Breast cancer is the second leading cause of cancer
death among women. Each year, approximately 200,000
women in the US are diagnosed with breast cancer, and
40,000 will die of the disease [15]. Treatment can
involve a difficult regimen of surgery, radiation therapy,
chemotherapy, and reconstructive surgery for those
women undergoing mastectomy. Even women who
experience five-year disease-free survival have reduced
quality of life during relatively extensive periods of treat-
ment [16].
The probability of cure or extended remission of
breast cancer depends on the stage of disease at diagno-
sis [17]. Mammography is part of a recommended set of
breast cancer screening procedures (along with clinical
breast exam and breast self-examination) whose main
objective is diagnosis at the earliest possible stage of dis-
ease. Some variability exists among national guidelines
for mammography frequency, but most guidelines
recommend annual mammography for women over 50
[18]. The main benefit of increased mammography rates
is in shifting the distribution of stage at diagnosis, and
therefore the subsequent survival probabilities, among
those women diagnosed with breast cancer [19]. The
National Committee for Quality Assurance (NCQA)
Health Employer Data and Information Set (HEDIS) for
managed care plans includes a measure of mammogra-
phy use, which is defined as the percentage of women
between 50 and 65 who have been continuously enrolled
in the plan for two years and have had at least one
mammogram in the past two years [20].
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There is some controversy about the extent to which
there are meaningful racial/ethnic disparities in mam-
mography rates. Recent national surveys have suggested
that black, Hispanic, and white women all receive mam-
mograms at approximately the same rate [21]. However,
analyses of Medicare and other claims data sets typically
show a disparity of 7-15 percentage points in mammo-
graphy rates, with black and Hispanic women less likely
to receive mammograms than non-Hispanic white
women [22,23]. These disparities have been found
within some individual managed care plans, suggesting
that at least some number of plans will find disparities
in mammography rates when analyzing their own
HEDIS data [24].
Eliminating a disparity in mammography rates would
involve raising rates in black or Hispanic women to the
level currently found for white women. For a typical
health plan with relatively high current mammography
screening rates, that might involve increasing the mam-
mography rate for minority women from 70% to 80%.
The question we addressed in this simulation was: What
would be the benefits to an employer in terms of atten-
dance and productivity at work, and medical care costs,
for an employed population of African-American
women if a typical disparity of 10% in mammography
rates were eliminated?
Mandelblatt et al [25] used a simulation modeling
approach to estimate the costs and benefits of improv-
ing breast cancer outcomes among African-American
women through either improved screening or improved
treatments after diagnosis. Their results showed a rela-
tively modest benefit for improved screening in a
hypothetical cohort of 40-year-old African-American
women. We used a similar modeling approach, but the
analyses were focused on the 50- to 65-year-old age
group that is the defined denominator population for
the HEDIS breast cancer screening measures, and the
annual mammography patterns being modeled were
selected to match those typically found among members
of managed care plans. We used published data specific
to African-American women on mammography rates,
distribution of stage at diagnosis, survival by stage, and
days worked to estimate the benefits of eliminating
disparities in mammography rates between African-
American and white women.
Asthma
Asthma is a common chronic disease affecting 10-20
million Americans in 2003 [26,27]. (Variation in esti-
mates depends on whether the specific measure is ever
having had asthma, having had an asthma attack in the
past 12 months, or report of currently having asthma.)
Asthma is more prevalent in African-Americans and
Hispanics than in non-Hispanic whites, so the burden of
morbidity and mortality related to asthma occurs
disproportionately in those groups [28]. Deaths from
asthma are rare [29], but morbidity in the form of acute
exacerbations and related days lost from work or school
is common [30]. Data from national surveys and other
studies suggest that members of minority groups experi-
ence more asthma-related lost work and school days
than whites, even among those with comparable asthma
severity levels [31,32].
National guidelines since 1991 recommend use of
inhaled preventive medications, including inhaled corti-
costeroids (ICS), as the preferred method of long-term
management for patients with persistent asthma [33].
(Patients with only mild, intermittent asthma may be
appropriately managed with acute, “rescue” medications
as needed.) Based on these guidelines, NCQA has
included a measure of Appropriate Medications for
Asthma in its HEDIS measures since 2000 [34]. The
measure is defined as the proportion of health plan
members with persistent asthma who have been pre-
scribed at least one of the approved preventive medica-
tions in the past year. The most recent average rate
reported by the NCQA for commercial managed care
plans publicly reporting their HEDIS data was approxi-
mately 70% in 2008, and the 90th percentile rate for
such plans was approximately 80% [35].
Data from a number of studies suggest that African-
American children and adults are less likely to receive
prescriptions for preventive medications (and use them)
than their white counterparts [36,37]. Since the medica-
tions are effective in all racial/ethnic groups and the
national guidelines do not make different recommenda-
tions for different groups, disparities in use of recom-
mended medications are presumed to be one of the key
underlying reasons for disparities in morbidity and mor-
tality [38,39]. Improving rates of appropriate medication
use in minority patients should result in a reduction in
disparities in measures like lost work or school days,
emergency room (ER) visit rates, hospital admission
rates, or deaths [40].
Our goal in this project was to model the effects of
improvements in appropriate medication rates for chil-
dren, adolescents, and adults, on lost school or work
days and on direct medical care costs [41,42]. To link
data on disparities in children’s use of asthma medica-
tions to an employer business case, we made the
assumption that an employed adult would have to take
one day off work for every day in which a child had an
asthma exacerbation requiring a physician office visit, an
ER visit, or a hospital admission [43]. The model specifi-
cally focused on the effects of reducing or eliminating
disparities in the HEDIS Use of Appropriate Medication
for People with Asthma measure [44]. The modeling
exercise asked the question of how many lost school or
work days would be averted by increasing medication
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use rates in minority populations to those observed in
non-Hispanic white populations. These benefits were
estimated over time periods ranging from one to five
years.
Methods
In calculating a business case for reduction of disparities
in HEDIS measures, we used Markov simulation models
to estimate the consequences, for defined populations of
African-American employees or health plan members,
of a 10% increase in HEDIS mammography rates or a
10% increase in appropriate medication use among
either adults or children/adolescents with asthma. These
improvements would correspond to elimination of dis-
parities of the magnitude often observed for those two
measures. Although we also report findings in terms of
quality-adjusted life years (QALYs) gained as a measure
of benefit to patients and society of reducing disparities,
the primary endpoints in modeling the employer per-
spective were direct medical care expenses and cost of
days missed from work. Our main analytic goal was to
determine whether there was a positive business case
for disparity reduction in either area, and if so, to deter-
mine whether the case was stronger in one clinical area
than another.
Mammography Simulation Model
The basic approach used in this study was a Markov
simulation model with annual cycles [45]. The model
was set up to simulate the key events related to the
diagnosis and treatment of breast cancer in a fixed
cohort of African-American women aged 50-65, given
different rates of mammography. All women in the
simulation cohort started without cancer, and they
either did or did not receive mammography in a given
year. In each year, women may or may not have devel-
oped cancer; if cancer was diagnosed, the probability of
advanced stage disease at diagnosis depended on
whether mammography had been performed that year
as part of an annual, biennial, or more infrequent sche-
dule of mammography.
Women who did develop cancer in one year started
the next year either in remission, with progressive dis-
ease, or dead, with probabilities depending on the stage
at diagnosis during the year of diagnosis. Women who
did not develop cancer in a given year started the next
year without cancer and, again, either did or did not
have mammograms. The model can be run for any
desired number of years; for this study, the time period
used was five years.
To assign values to the model, there were two health
endpoints being modeled and two employment-related
endpoints. In the mortality or survival analysis, the
“dead” state was valued at 0 and all other states are
valued at 1. For analysis of QALYs, each state was
assigned a utility value between 0 and 1, based on values
in published literature and a set of assumptions about
how much of each year is spent in each state. (For
example, a woman who dies of cancer in a given year
does not die on the first day of the year, so she accumu-
lates some QALY values during the part of the year in
which she is alive.)
For analysis of employment endpoints, the probabil-
ities of working and the average work loss days for
those who are employed were estimated, on the basis of
published literature, for each state in the model.
Employment probabilities were estimated in an employ-
ment equation which included all the relevant factors
affecting employment status - for example, breast cancer
status, exogenous variables (age, race, education, etc.),
and health insurance. Probit estimates were the most
commonly used method to derive the probability of
employment. The number of days lost from work due to
undergoing treatment was also estimated. Then, mone-
tary values of reductions in employment and increases
in absenteeism for employers (e.g., cost to employer of
replacing an employee missing a day of work due to ill-
ness) were calculated based on published data (see
Table 1 for all model input parameters and sources).
In general, we used estimates of absenteeism among
women remaining employed, rates of women leaving
work entirely, and medical care costs to employers for
the six months following a new breast cancer diagnosis.
All three are costs to employers that could be affected
by increasing mammography rates and consequent shifts
to earlier stage diagnoses. Based on the annual average
wage of $21.31 per hour [46], the cost of lost productiv-
ity to the employer is the hours lost multiplied by
hourly wage, assuming 8 hours worked per day and that
absenteeism is the only cause of lost productivity.
When employees decide or must leave the workforce
because of the severe illness, a turnover cost is incurred.
The turnover cost to the employer comprises the
expenses of recruiting and training new employees.
Turnover costs generally include time and monetary
costs to select, recruit and train a replacement, and lost
productivity. A study based on the US Department of
Labor estimated the costs to replace an employee to
average 33 percent of the new hire’s salary [47]. Assum-
ing 2080 hours per year, using the estimated average
hourly wage, the annual turnover cost is $14,627.
Medical costs of employed patients are also a burden
for employers. In the model, costs for breast cancer care
paid by private insurers (as estimated from available
published literature) were presumed to represent costs
to employers, since this would be literally true for self-
insured employers, and true in a less direct sense for
other employers as their insurance premiums would
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Table 1 Input Parameters for Mammography Simulation Model
Base Model Parameter Range Used in
Sensitivity Analysis
Source(s)
State Transition Probabilities
Annual Incidence of Cancer .003 [64-67]
Probability of Annual, Biennial, and Sporadic Mammogram
Patterns
HEDIS 70%
- Annual = 0.197
- Biennial = 0.395
- Sporadic = 0.270
- None = 0.138
[59-63], authors’ calculations
HEDIS 80%
- Annual = 0.242
- Biennial = 0.483
- Sporadic = 0.182
- None = 0.093
Increase in Probability of Mammography Following False
Positive
.10 increase relative to probability
in absence of false positive
[50]
Probability of Cancer Found, Given Screening Pattern - Annual = .003
- Biennial = .003
- Sporadic = .005
- None = .008
[68,69]
Distribution of Stage at Diagnosis with (W/O) Mammogram Annual
- In Situ = 0.13
- Stage I = 0.41
- Stage II = 0.37
- Stage III = 0.07
- Stage IV = 0.02
[70-76]
Biennial
- In Situ = 0.13 (0.04)
- Stage I = 0.41 (0.32)
- Stage II = 0.37 (0.43)
- Stage III = 0.07 (0.13)
- Stage IV = 0.02 (0.08)
In Situ = 0.04 - 0.21
Stage I = 0.32 - 0.57
Stage II = 0.16 - 0.43
Stage III = 0.04 -
0.13
Stage IV = 0.02 -
0.08
Sporadic
- In Situ = 0.17 (0.04)
- Stage I = 0.29 (0.32)
- Stage II = 0.40 (0.43)
- Stage III = 0.09 (0.13)
- Stage IV = 0.05 (0.08)
None
- In Situ = (0.04)
- Stage I = (0.32)
- Stage II = (0.43)
- Stage III = (0.13)
- Stage IV = (0.08)
Probability of Remission in Year of Diagnosis, Given Stage
at Diagnosis
Stage I = 97.5%
Stage II = 94.0%
Stage III = 81.0%
Stage IV = 66.0%
[73,77]
Probability of Death from Other Causes .01 [78,79]
Probability of Continued Remission vs. Recurrent Disease,
Given Stage at Diagnosis and Initial Remission
Stage I = 0.975
Stage II = 0.94
Stage III = 0.81
Stage IV = 0.66
[73,77]
Probability of Death, Given Recurrent or Progressive
Disease
0.79 [73,77]
State Values
Utility of Well, Non-Cancer States 1.0 [80-86]
Utility of Newly Diagnosed Cancer, by Stage at Diagnosis Stage I = 0.90
Stage II = 0.85
Stage III = 0.81
Stage IV = 0.81
Stage I = 0.80 - 0.98
Stage II = 0.80 - 0.98
Stage III = 0.80 -
0.98
Stage IV = 0.80 -
0.98
[80-86]
Nerenz et al. BMC Medical Research Methodology 2011, 11:31
http://www.biomedcentral.com/1471-2288/11/31
Page 5 of 22
reflect recent costs of employees’ cancer care. Initial and
terminal phases of breast cancer treatments are the
most costly [48].
Whenever possible, probabilities of events or utility
values were obtained from studies of African-American
women. The structure of the model is illustrated in
Figures 1 and 2. The model was run for five annual
cycles. All women started alive without cancer diagno-
sis in one of the four groups based on pattern of mam-
mography, since the HEDIS denominator population
definition excludes women with cancer diagnoses.
Figure 1 shows the starting states for the model. At
the beginning of the simulation, each woman in the
simulation cohort was assigned to one of four groups
based on her pattern of receipt of mammograms over
multiple years - annual, biennial, sporadic, or none.
The probabilities shown for each group reflect the
probabilities of being in each group at the start of the
simulation, for the 70% HEDIS rate scenario. Figure 1
also shows the set of states following each of the four
“mammography pattern” groups.
Figure 2 shows the initial options for women who
received a mammogram in a given year under any of
the three patterns (annual, biennial, sporadic) that
would include the receipt of a mammogram during a
five-year simulation period. (The same options were
included in the model for women not receiving mam-
mograms, but are not shown here.) The key feature of
the model is the stage of cancer at diagnosis, which
determines the subsequent probabilities of remission
and survival. The triangle symbols at the right side of
the figure signify that women in those branches return
to the specific named states to start the next annual
cycle of the model, or die and no longer continue in the
simulation cycle.
The input parameters for the model are summarized
in Table 1. The key parameters were: probability of
annual, biennial, and less frequent mammography; the
incidence of breast cancer in the population of
employed African American women aged 50-65; distri-
bution of stage at diagnosis given a particular pattern of
mammography; probability of remission or progressive
disease following initial treatment given stage at diagno-
sis; probability of continued remission vs. recurrence
given remission after initial treatment; probability of
death given recurrence or progressive disease; annual
probability of death from other causes in African-
American women aged 50-65; utilities assigned to
various disease, treatment, or disease-free states; prob-
ability of employment given cancer diagnosed at specific
stages; and medical care costs associated with cancer
diagnosed at specific stages.
Table 1 Input Parameters for Mammography Simulation Model (Continued)
Utility of Undergoing Treatment, by Stage at Diagnosis Stage I = -0.10
Stage II = -0.20
Stage III = -0.25
Stage IV = -0.25
[80-86]
Utility of Progressive Disease 0.40 0.30 - 0.69 [80-86]
Probability of Employment - no Cancer 1.00 Arbitrary - simulation
assumes women employed
Probability of Employment in Year of Cancer Diagnosis, by
Treatment Stage
In Situ = 0.86
Stage I = 0.70
Stage II = 0.60
Stage III = 0.50
Stage IV = 0.40
[88-94]
Probability of Employment in Year of Cancer Diagnosis, by
Remission Stage
Stage I = 0.94
Stage II = 0.88
Stage III = 0.81
Stage IV = 0.75
[88-94]
Probability of Employment - Progressive Disease 0.56 [88-94]
Other Values
Costs of Initial Treatment, by Stage at Diagnosis Stage I = $ 22,488.00
Stage II = $ 27,213.00
Stage III = $ 29,220.00
Stage IV = $ 31,476.00
[48]
Costs of Treatment - Recurrent or Progressive Disease $ 33,000.00 [48]
Cost of Mammogram $ 81.86 Federal Register, 2007
Cost of Followup after False Postive Test $533 [106]
Hourly Wage for Time Missed from Work $ 21.31 Department of Labor, May
2007 [46]
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Sensitivity Analysis
Sensitivity analyses were conducted to determine how
the life expectancy, QALYs, employment rates, working
hours missed plus turnover costs and medical care costs
change when the distribution of stage at diagnosis in the
simulation model moves from the most “pessimistic”
one (i.e., least benefit due to mammography) to the
most “optimistic” one (i.e., greatest effect of mammogra-
phy on stage). In addition to the base model described,
four more versions of the model with different combina-
tions of distribution of cancer stage from Table 1 were
defined and used for sensitivity analysis. Based on the
different combinations, models are considered as mov-
ing from the most pessimistic to the most optimistic
models. The definitions of all five models are summar-
ized in the Appendix.
The base model did not include the costs or effects of
false-positive mammograms, but one recent review sug-
gested that over 10% of mammograms will be read as
suspicious for cancer and then followed up with biopsy
or other tests, even though cancers are not found in the
vast majority of these [49]. Two additional versions of
the model were created - one with an explicit cost
added for false positive tests requiring additional fol-
lowup, and another with those costs included and a
slight increase in the subsequent probability of mammo-
graphy after a false positive test [50].
Other input parameters were not included in sensitiv-
ity analyses either because they had one widely accepted
value (e.g., annual cancer incidence rate) or because
they could be set arbitrarily to fit any specific new appli-
cation of the model (e.g., increase in mammography
Figure 1 Mammography pattern groups and starting states of simulation model.
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rate; hourly rate for employees). The relationship
between mammography and stage distribution at diag-
nosis seemed to be the relationship with greatest varia-
tion in published values and greatest potential impact
on model outputs.
Asthma Basic Model Structure The basic modeling
approach was a Markov model simulating the likelihood
of various events like acute exacerbations, ER visits or
hospital admissions, lost school or work days, or deaths
as a function of taking or not taking appropriate medi-
cations. The model (illustrated in Figure 3) was struc-
tured to capture the range of possible events during a
month. Hypothetical patients in the model began each
month either taking or not taking appropriate
medications, and then experienced events during the
month with probabilities that depended on whether or
not they were taking medications. At the end of each
month, patients “cycle back” and began a new month
either taking or not taking appropriate medications. The
model was run for 12, 24, 36, 48, or 60 monthly cycles
to simulate experience over time periods from one to
five years.
The model is similar in structure to that developed by
Paltiel et al [51], but does not include forced expiratory
volume (FEV1) as a core concept, because we were
unable to find adequate data for that approach specific
to individual racial/ethnic minority groups. When possi-
ble, parameters from the Paltiel model were used in our
Figure 2 Breast cancer stages and treatments in simulation models.
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model to try to maximize comparability across the two
modeling approaches.
The structure of the model is illustrated in Figures 3,
4, and 5. Figure 3 shows the first set of branches, or
starting states. Figure 4 shows the next set of state tran-
sition options, with associated monthly probabilities in
the situation where a child is not using appropriate
medications. The same transition options exist in the
model for children using appropriate medications, but
with different probabilities. Figure 5 illustrates the com-
plete set of transition states, for a child not using appro-
priate medications and experiencing an exacerbation
requiring an ER or urgent care visit during the month.
Similar sets of branches follow from other “exacerba-
tion” branches, but with different probabilities.
The primary input parameters for the model are sum-
marized in Table 2. They included: probability of use of
appropriate controller medications in a month, probabil-
ity of exacerbations in a month given use or non-use of
controller medications, probability of ER or urgent care
visit or hospitalization given exacerbation, number of
days missed from work given exacerbations of varying
severity, medical care costs associated with treatment of
exacerbations of varying severity, costs of controller med-
ication [52], and utilities associated with specific states of
exacerbations and freedom from exacerbations. The
models were run for both adults and children; for chil-
dren, days missed from school was used instead of days
missed from work, but in analyzing days missed from
work to calculate a business case from the employer per-
spective, it was assumed that an employed parent would
miss a day of work for every day a child with asthma was
out of school because of an exacerbation.
Patients are not consistent from month to month or
year to year in their use of medications. Although a rate
of adherence may be stable over time for a large
population, individuals can alternate between periods of
use and non-use, and the Markov model structure
allows for this factor to be included. We presumed that
medication use would be generally stable from month to
month, but that some individuals taking medication and
experiencing no exacerbations in a given month would
not use medications in the following month (in various
versions of the model we used proportions of 5-10%).
Even some individuals experiencing ER visits or hospita-
lizations may not use medications in the following
month (perhaps believing them to be ineffective); we
estimated this proportion as 1%, with 99% of those
experiencing ER visits or hospitalizations continuing on
medications.
Among those not using medications in a given month,
we presumed that 1% of those not experiencing exacer-
bations would begin to use medications in the following
month, that 15% of those experiencing an exacerbation
would begin to use medications in the following month,
and that 25% of those requiring an ER visit or hospitali-
zation would begin using medications in the following
month.
In the absence of published data on these transitions
among minority group patients with asthma, some of
the transition probabilities are somewhat arbitrary. They
were adjusted to produce the effect of gradually rising
use of medication for the group as a whole over time.
This trend of gradual increase is consistent with
national data on improvement in the HEDIS asthma
medication measure over time [9].
Results
Breast Cancer
Life Expectancy
In Table 3, life expectancy is expressed as the life expec-
tancy for a typical African-American woman in the
Figure 3 Initial states for Markov model of appropriate medications for asthma.
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Figure 4 Second set of state transition options, illustrated for the initial state of not using appropriate medications.
Figure 5 Additional state transition options, given the occurrence of an exacerbation requiring an ER or urgent care visit.
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Table 2 Input Parameters for Asthma Medication Model
Base Model
Parameter
Range Used in
Sensitivity
Analysis
Source(s)
State Transition Probabilities
Probability of Asthma Medication Use 80% 70% (90%) [37,95,96,99]
Probability of Exacerbation not requiring ER visit or
Admission
With Medication
= 0.27
W/O Medication
= 0.53
Same as 80% [32,95,98]
Probability of Exacerbation Requiring ER Visit, not
Admission
With Medication
= 0.0382
W/O Medication
= 0.0756
Same as 80% [95,98,102-104]
Probability of Exacerbation Requiring Admission With Medication
= 0.0035
W/O Medication
= 0.0069
Same as 80% [49,101]
Probability of Medication use Following
Exacerbation
With Medication
- no ER visit or
Admission =
0.96
- ER visit, no
Admission =
0.99
- Admission =
0.99
With Medication
- no ER visit or
Admission = 0.97
(0.99)
- ER visit, no
Admission = 0.99
(0.99)
- Admission = 0.99
(0.99)
Authors’ values, constrained by requirement that
overall medication use be constant over entire
simulation
W/O Medication
- no ER visit or
Admission =
0.25
- ER visit, no
Admission =
0.30
- Admission =
0.30
W/O Medication
- no ER visit or
Admission = 0.15
(0.4)
- ER visit, no
Admission = 0.25
(0.45)
- Admission = 0.25
(0.45)
Probability of Medication Use Following Month of
No Exacerbation
With Medication
= 0.96
W/O Medication
= 0.01
With Medication =
0.95 (0.965)
W/O Medication =
0.01
Authors’ values, constrained by requirement that
overall medication use be constant over entire
simulation
Probability of Death from Other Causes 0.0001 Same as 80%
State Values
Utility of Month without Exacerbation With Medication
= 0.0748
W/O Medication
= 0.0756
[49]
Utility of Exacerbation not requiring ER visit or
Admission
With Medication
= 0.0706
W/O Medication
= 0.0712
[49]
Utility of Exacerbation requiring ER visit, no
Admission
With Medication
= 0.0698
W/O Medication
= 0.0704
[49]
Utility of Exacerbation requiring Admission With Medication
= 0.0649
W/O Medication
= 0.0654
[49]
Days Missed per month from Work or School from
Exacerbation not requiring ER visit or Admission
3 days [95,98]
Days Missed from Work or School from
Exacerbation requiring ER visit, no Admission
4 days [95,98]
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HEDIS denominator population, over a five-year period,
with mammography rates increasing by 10% from 70%
to 80%. These results suggest that an increase of 10% in
the mammography rate for African-American women
would add a total of 15 years in a denominator popula-
tion of 10,000 women, or 1-2 years in a denominator
population of 1,000 women.
Quality-Adjusted Life Years
Table 3 also shows the effect of a 10% increase in
HEDIS mammography rate on the five-year cumulative
QALYs for an African-American woman in the 50-65
age cohort. As in the case of life expectancy, the gain is
relatively modest - approximately 2 QALYs gained per
1,000 women in the cohort over five years. Improving
mammography rates for African-American women from
70% to 80% could be expected to add 24 quality-
adjusted life years in a population of 10,000 women
aged 50-64. The QALY gains are greater than the life
expectancy gains because some of the women alive at
the end of five years after having had cancer would have
avoided the treatments associated with late-stage cancer
at diagnosis by having more frequent mammography.
Costs Associated with Absenteeism and Workforce Turnover
In the scenario with a 70% HEDIS mammography rate
among African-American women aged 50-65, an
employer could expect to incur approximately $178 of
cost per woman in the cohort related to absenteeism
and employer turnover following breast cancer diagnosis
and treatment in that cohort. When the mammography
rate rises to 80% (disparity in mammography elimi-
nated), the expected cost related to absenteeism and
turnover dropped to approximately $166 (savings of $12
per woman in cohort) because of less absenteeism and
turnover among women with less advanced stage of can-
cer at diagnosis. Therefore, in a cohort of 100 women,
the projected savings would be $1,200 over five years;
$12,000 in a cohort of 1,000 women, etc.
Direct Medical Care Costs
Similarly, an employer in the 70% HEDIS mammogra-
phy scenario could expect to incur approximately $1,123
Table 3 Mammography Model Outputs, with Sensitivity Analysis Results
Model Output Version of Simulation Model*
Rate Base I II III IV
70% 4.85705 4.85599 4.85731 4.85756 4.85772
Life Expectancy 80% 4.85856 4.85735 4.85887 4.85919 4.85929
Diff 0.00151 0.00136 0.00156 0.00163 0.00157
70% 4.84524 4.84369 4.84570 4.84617 4.84643
QALYs 80% 4.84762 4.84586 4.84820 4.84877 4.84894
Diff 0.00238 0.00217 0.00250 0.00260 0.00251
70% 4.84087 4.83922 4.84135 4.84183 4.84211
Employment Rate 80% 4.84357 4.84170 4.84417 4.84475 4.84494
Diff 0.00270 0.00248 0.00282 0.00292 0.00283
70% $178.1132 $181.9811 $176.8969 $175.6906 $175.1368
Cost to Employer of Missed Work 80% $165.5864 $169.9384 $164.0923 $162.6172 $162.2439
Diff $-12.5268 $-12.0427 $-12.8046 $-13.0734 $-12.8929
70% $1123.3621 $1142.1542 $1116.8214 $1110.3160 $1106.7010
Medical Care Cost 80% $1085.6956 $1107.1215 $1077.6608 $1069.7061 $1067.2694
Diff $-37.6665 $-35.0327 $-39.1606 $-40.6099 $-39.4316
*Models vary in terms of the shift in distribution of stage at diagnosis attributed to increase in mammography rates. Model I is least optimistic in terms of the
amount of stage shift produced: model IV is most optimistic.
Table 2 Input Parameters for Asthma Medication Model (Continued)
Days Missed from Work or School from
Exacerbation requiring Admission
7 days [33,98]
Cost of Doctor Office Visit for Exacerbation $155.44 [105], authors’ calculation
Cost of ER Visit $1,080.00 [105], authors’ calculation
Cost of Admission $13,512.00 [105], authors’ calculation
Cost of Monthly Asthma Medications $112.00 [50]
Hourly Wage for Time Missed from Work $21.31 Department of Labor, May 2007 [46]
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in medical care costs per employed African-American
woman aged 50-65 related to new breast cancer diag-
noses; that estimate became $1,086 as the HEDIS mam-
mography rate rose to 80%. Again, the main reason for
the effect is lower medical care cost associated with less
advanced stage at diagnosis. The projected saving with a
10% increase in mammography rate is $38 per woman
in an employed cohort over a five-year period.
The Employer “Business Case” - Combination of
Absenteeism, Turnover, and Medical Care Costs
The combined savings per employed African-American
woman aged 50-65 associated with a 10% increase in
HEDIS mammography rate, from all three areas com-
bined, was $50. For an employer with 100 African-
American women in that age group, then, the projected
savings associated with eliminating a 10% disparity in
mammography rates would be $5,000. A quality
improvement or health education initiative designed to
enhance mammography screening, and that did in fact
raise mammography rates by 10%, would have to cost
$5,000 or less to be cost-saving.
Sensitivity Analysis
Several alternative versions of the model were run with
varying assumptions about stage distributions with or
without mammography. In the alternative models, 13-16
lives per 10,000 women would be saved as a result of
increasing mammography rates in African-American
women by 10%. The small effects of variations of the
model reflect the low incidence of cancer in any one- or
two-year period, and that the shift in stage at diagnosis
as a result of mammography is relatively modest, even
using the most optimistic data on stage distributions in
the literature.
The results of these sensitivity analyses are shown in
Table 3. The pattern observed across all major output
parameters in the model is similar. As expected, a
more optimistic estimate of the effect of mammogra-
phy on stage distribution is associated with a larger
effect on QALYs, cumulative employment, and costs to
employers for time missed from work. The size of the
differences across different versions of the model is
small, suggesting that the model results are robust
across all reasonable estimates of the effect of mam-
mography on stage at diagnosis from the published
literature.
Adding an explicit cost for false positive tests had a
somewhat more significant effect on model outputs,
although in all cases the direct medical care costs were
still slightly lower in the 80% mammography scenario
than in the 70% scenario. The cost saving was reduced
from $50 to $18 in the model that included just the
direct cost of false positives ($1,248 vs. $1,230), and to
$17 in the model that included both costs of false posi-
tives and a slight increase in likelihood of mammogra-
phy in subsequent cycles after a false positive.
Asthma
Life Expectancy
Probabilities of death were extremely low in all versions
of the model, and did not vary significantly with
improvements in medication use rates from 80% to 90%.
Quality-Adjusted Life Years
The effect of increasing appropriate medication use on
QALYs depends partly on assumptions made on the
number of days spent at home during acute exacerba-
tions, and the extent to which one applies a “QALY
penalty” for spending time in an ER or hospital during
an exacerbation. The effects of variations on these para-
meters are relatively small, though, so the results shown
in Table 4 are typical of the range of QALY benefits to
be obtained over five years by improving appropriate
medication rates from 80% to 90% in African-American
or Hispanic children or adults. There was a gain of
approximately 1.5-2 QALYs per 1,000 people with
asthma in the denominator population, per year, that
would be obtained by eliminating a 10% disparity in
appropriate medication use (raising the rate of medica-
tion use from 80% to 90%).
Costs Associated with Absenteeism
From the employer perspective, there is a gain of over
one full work day per year per African-American
employee with asthma by eliminating a disparity of 10%
in use of appropriate medications. There was also a gain
of over one school day per year per African-American
child or adolescent with asthma by eliminating a dispar-
ity of 10% in use of appropriate medications.
A reduction in days missed from work of over one day
per year, or five to six days over a five-year period,
would yield a savings to the employer of $866.04 per
adult employee with asthma over that five-year period.
Table 4 Gains in QALYs, Work Days for Adults, and School Days for Children Associated with 10% Changes in Asthma
Medication Use Rates
Model Output Appropriate Medication Use Rate Gain Per 10% Increase in Rate
60% 70% 80% 90%
Cumulative QALYs - 5 Years 4.37627 4.37996 4.38387 4.38738 3-4 QALYs Per 1,000 People
Cumulative Work Days Over 5 Years - Adults 1,216.39 1,221.74 1,227.41 1,232.49 5-6 Work Days Per Adult
Cumulative School Days Over 5 Years - Children 815.79 821.13 826.79 831.47 4-6 School DaYs Per Child
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If we assume that an employed parent would take one
day off work for every day missed away from school for
a dependent child with asthma, the savings to that par-
ent’s employer associated with a reduction in disparity
in medication use for children with asthma would be
$852.40 per employed parent. The annual savings would
total $343.69. The effects of more conservative assump-
tions about days missed by employed parents for chil-
dren with asthma exacerbations are shown in Table 5.
Direct Medical Care Costs
Eliminating a disparity of 10% in asthma controller med-
ication use would produce a savings of $793.72 per
patient in terms of reduction in costs associated with ER
and urgent care visits and hospitalizations over a five-
year period. However, when the additional controller
medication costs associated with that 10% increase are
included in the calculation, the overall savings in direct
medical care costs associated with that 10% increase
drop to $86.50 per person over the five-year period, or
$17.30 per employee with asthma (or parent of child
with asthma) per year.
Comparison of Business Cases for Mammography vs.
Asthma Medication
Table 5 summarizes the employer business case for
reducing disparities either in mammography rates or in
asthma medication use rates, using the total of direct
medical care expenses and indirect expenses associated
with days missed from work. Regardless of whether fac-
toring into the calculation the turnover cost for women
with breast cancer, there is a greater potential financial
gain related to eliminating a disparity in asthma medica-
tions than there is for eliminating a disparity in mam-
mography rates.
Discussion
A number of caveats accompany the presentation of
these findings. First, any simulation model inevitably
involves some distortion of actual clinical events,
although the model used here was designed to simulate
the key events as closely as possible. Some potentially
relevant and unaccounted-for clinical factors include
disparities follow-up of abnormal mammograms, differ-
ences in access to treatments (beyond those already
reflected in survival rates), or differences in subsequent
mammography patterns as a result of positive or nega-
tive mammograms.
Second, the models and their calculations were inevi-
tably dependent on the limitations of published data.
For some parameters, available data were several years
old, and may not fully reflect clinical practice today.
Nevertheless, models can easily be updated to take into
account new information as it becomes available.
Third, the model had to use some parameters that
were not specific to African-American women with
breast cancer or adults or children with asthma. Utilities
for specific health states, for example, were taken from
studies of large, multi-ethnic or predominantly white
populations. Again, future models can take these factors
into account as group-specific information becomes
available.
Given these constraints, we were encouraged by the
extent to which our findings matched those of other
investigators using similar, but not identical, analytic
approaches. Mandelblatt et al [25] estimated that two
alternative approaches to improving mammography
rates among African-American women would add
approximately .0008 years of life expectancy to a
40-year-old woman over a period slightly in excess of
20 years. Our results are also reasonably consistent
with a recent Canadian study showing 3 lives saved
per 25,000 mammograms [53]. In all of these analyses,
the health benefits of improved mammography rates
are modest relative to other potential interventions
like reducing disparities in cancer treatment or
improving care for other clinical conditions [54].
Adopting a longer time perspective would increase
these estimates, as women avoiding late-stage breast
cancer because of more frequent mammography in
any five-year period continue to survive for many
years after this period. From a public health perspec-
tive, these gains in life expectancy over longer periods
of time justify investments in mammography. A time
horizon longer than five years is not typically used to
Table 5 Comparison of Key Model Outputs Relevant to Employer Business Case for Disparity Reduction
Disparity-Reduction Intervention Direct Medical Care
Costs - Change Per
Person
Days Off Work -
Change Per Person
Indirect Costs -
Change Per
Person
Total - Change Per
Person
Increase HEDIS Mammography Rate in
African American Women by 10% (70%-80%)
$ - 37.66 -0.59 $ -12.53 (no
turnover cost) $
-140.03
$ -50.19 (no turnover cost)
$-177.69 (with turnover)
Increase HEDIS Appropriate Medication Use
in Adults by 10% (80-90%)
$ - 793.72 - 5.08 $ -866.04 $ -1,659.76
Increase HEDIS Appropriate Medication Use
in Adults by 20% (70-90%)
$ - 1,680.26 - 10.75 $ -1,832.66 $ -3,512.92
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judge the benefits of investments in quality improve-
ment programs.
From the employer business case point of view, the
effects of eliminating disparities in mammography on
employer-related outcomes (cost of absenteeism, cost of
employee turnover, and direct medical care expenses)
were positive, but modest. A 10% increase in mammo-
graphy rates is estimated to save $12-$13 per employed
African-American woman over a five-year period due to
reduced costs of absenteeism, and an additional $37-$38
per woman in reduced medical care expenses. There is
a total savings to employers, then, of $50 per employed
African-American woman over five years, following a
10% improvement in mammography rates, if one
assumes no turnover ($17-18 if the costs are false posi-
tive mammograms are included); the savings is approxi-
mately $180 per employed woman if projected turnover
costs are included.
Since we do not yet have a large literature on the
costs of interventions needed to improve mammography
rates among African-American women, it is not yet pos-
sible to extend the models into the realm of cost-effec-
tiveness analysis and compare the cost-effectiveness of
eliminating disparities in mammography rates to those
of eliminating disparities in other areas like glycemic
control in diabetes or medication adherence in asthma.
The calculation above, though, suggests that a disparity-
reduction intervention that can be carried out for less
than $50-$180 per woman in the target group can be
cost-saving.
The findings for asthma were more favorable from an
employer point of view. The reduction in direct medical
care expenses and the reduction in costs due to absen-
teeism or diminished productivity related to elimination
of a disparity in medication usage were both signifi-
cantly larger than those estimated for mammography.
We also do not have data on costs of interventions to
reduce disparities in asthma medication usage, but an
intervention would be cost-saving if it could be carried
out for less than $1,660 per person and if had the effect
of raising medication adherence rates in African-Ameri-
can employees or dependents by 10%.
Similar analyses have been conducted to create a
rationale for choosing measures for pay-for-perfor-
mance programs or for prioritizing quality improve-
ment initiatives [55-57]. As more data become
available with which to populate simulation or decision
analysis models, it should be possible to have an
empirical basis for deciding among competing priori-
ties for disparity-reduction initiatives, and for develop-
ing an employer business case for those initiatives. A
strong employer business case would help support
efforts by health plans and provider organizations to
reduce and eliminate disparities [58].
The simulation model approach illustrated here could
be used to address related questions in a broader set of
disparities in domains of disease prevention, early detec-
tion, and disease treatment. In general, the models
require one or more well-defined endpoints of either
clinical or economic significance (e.g., deaths, QALYs,
costs) and then information necessary to define the
probabilities of essential intermediate clinical or health
states leading to those endpoints. For example, a model
of the business case for addressing disparities in treat-
ment for early-stage lung cancer would include prob-
abilities of surgery for early-stage cancer for various
racial/ethnic groups, probability of recurrence or pro-
gression following surgery, probability of recurrence or
progression following other treatment approaches
(including no treatment), duration and quality of survi-
val given alternative treatments, and patterns of employ-
ment and work attendance given alternative treatments
and related disease trajectories. The specific form and
key elements of various models will naturally vary from
one to the other, but we hope that the examples
described here will illustrate the potential of the
approach.
Conclusions
A simulation model approach can be used to estimate
the benefits to employers and to other stakeholders of
initiatives to reduce racial/ethnic disparities in quality of
health care. The results of these simulation models can
serve as part of a “business case” for disparities reduc-
tion. Using mammography screening and asthma medi-
cation use as examples, we demonstrate that this
approach can be used to compare the benefits of dispar-
ity reductions in different clinical domains.
Appendix - Detail on Model Parameters
I. Breast Cancer Screening Model
State Probabilities
Mammography Reisch et al [24] reported a 6% differ-
ence in rates of screening mammography between
African-American and white women enrolled in a health
maintenance organization (HMO) from 1983 to 1990,
and a 9% difference in the first part of that period
(1983-1987). Corresponding national figures for the
same time periods showed a disparity in mammography
screening rates of 7-10%. Burns et al [59] reported a 6%
difference in mammography rates between white and
black women over 65, using Medicare Part B billing files
from 10 states in 1990. O’Malley et al [60] reported a
larger disparity among women in North Carolina in
1988, with 36% of white women reporting having had a
mammogram in the past year vs. 17% of black women.
Data from the 1998 National Health Interview Survey
showed a 4.7% disparity in “recent mammograms”
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among women over 65 [61]; a slightly smaller disparity
(3.6%) was noted in the same data set between African-
Americans and whites among women aged 40-64 [62].
Rates for Hispanic women aged 40-64 were 10.8% lower
than those of white women.
Mammography rates have been rising since some of
these data were collected in the 1980s, and data from
the NCQA’s State of Health Care Quality report in 2005
(when the age bands for the HEDIS mammography
measure were the same as used in our analysis) show
the mean national screening rate in HMOs at 72.0% for
commercial enrollees and 53.9% for Medicaid [35].
Our project assumed a “base” scenario in which
screening rates using the HEDIS definition for white
women were 80% and African-American women were
70%. Reducing the disparity in screening rates would
involve raising the rate of screening in African-Ameri-
can women from 70% to 80%. The consequences of
mammography rates of 60% and 90% were also exam-
ined to expand the range of applicability of the model.
The HEDIS measure definition only requires a mam-
mogram once in two years rather than annually. Because
most national guidelines recommend annual mammo-
grams for women in the 50-65 age group, and because
the structure of the Markov model was built around
annual cycles, it was necessary to identify patterns of
annual, biennial, and less frequent mammograms that
would be consistent with published literature on mam-
mography screening and on the observed HEDIS mam-
mography rates.
These patterns were estimated using data from
Blanchard et al [63], who reported that twice as many
African-American women who had had at least one
mammogram in five years had biennial vs. annual mam-
mograms. Among women having any mammograms in
five years, the proportions with annual, biennial, or
“sporadic” mammograms (defined as one in five years)
were .23, .46, and .31, respectively. These ratios were
used to estimate the proportion of women in a health
plan population who would have to receive annual,
biennial, “sporadic,” or no mammograms to obtain
HEDIS two-year mammography rates of 60%, 70%, 80%,
or 90% [Additional File 1: Appendix Table 1].
For sake of simplicity, it was assumed that women’s
screening patterns would remain the same over the five-
year model period. In subsequent model cycles, then,
the probability of mammography was dependent on the
screening pattern assigned in the initial cycle and
whether or not a mammogram had occurred in the
most recent cycle.
In one of the models run for sensitivity analysis, the
probability of mammography in a later cycle after a false
positive was increased by 10% in relative terms (e.g.,
from .182 to .20) [50].
Cancer Incidence Mammography screening detects
either newly incident cancers, cancers missed in earlier
screening rounds, or prevalent cancers in women who
have not had previous mammograms. In a population of
women who are members of an HMO and who are gen-
erally getting regular screening, most of the cancers
identified in any given year will be incident cases.
Among women having annual mammograms, then, the
number of cancers identified in any cycle can be esti-
mated by using data on annual incidence of cancers
among African-American women in the relevant age
bands. Incidence rates can also be estimated by pub-
lished studies of cancers identified in mammography
screening programs.
The annual incidence rate for African-American
women aged 50-65 represents a lower bound on an esti-
mate of number of cancers identified through mammo-
graphy, since it would presume no “old” cancers to be
found. SEER data from the National Cancer Institute
provide several estimates of annual incidence for Afri-
can-American women in the 55-59 or 55-60 age band
(representing the middle of the HEDIS age group):
.00267 [64], .00275 [65], .00282 [66]. The minor varia-
tion seems to reflect the specific time period of SEER
data being examined. Leung et al [67] also provide an
estimate of annual incidence for African-American
women aged 50-69 as .0025.
There are several published studies of cancers
detected during mammography screening programs for
African-American women. Estimates range from 1.12 to
21 cancers per 1,000 women screened. The lowest esti-
mate is for interval cancers between mammograms two
years apart; the highest estimate is for first screens
among women with a family history of cancer and gen-
erally no previous mammograms. Two of the studies
found 3 cancers per 1,000 mammograms in second
screening rounds [68,69]; this situation is perhaps most
closely analogous to the HMO scenario being modeled
in which most women will have had one or more pre-
vious mammograms.
The base case scenario used 3 cancers per 1,000 as the
estimate of annual incidence in a population of African-
American HMO members aged 50-64 who receive
either annual or biennial mammograms. Five cancers
per 1,000 mammograms was the incidence estimate for
women with sporadic mammography patterns; 8 cancers
per 1,000 for women having cancer detected clinically in
an annual cycle in which they did not receive a mam-
mogram. The rate of 8 per 1,000 rate was chosen as a
middle-range estimate between 5 per 1,000 and the 10
per 1,000 rate reported by Kerlikowske et al [69] for
first screenings.
Stage at Diagnosis with Mammography Several studies
[70-74] report distributions of stage of cancer at
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diagnosis for African-American women receiving mam-
mograms [Additional File 1: Appendix Table 2].
Data from Jacobellis and Cutter [70] [Additional File
1: Appendix Table 2] represent a relatively favorable
estimate of distribution of stage at diagnosis in stages III
and IV, but have a relatively low percentage of cases
identified as cancer in situ. These figures were chosen
for the base case model for women with annual or bien-
nial mammograms because they represented a middle-
range estimate of the benefit of mammography. We
used the same stage distribution for the annual and
biennial schedules because of the finding of White et al
[75]. The stage distribution reported by Yood et al [72]
was used in the base case model for the “sporadic”
mammogram scenario, since it was derived from a
population of African-American women who were
members of a managed care plan, with a range of mam-
mography screening patterns. Data from Bibb [74] in
Table 2 represent a “best case” estimate of stage distri-
bution; these figures were used in sensitivity analyses as
an upper bound of the benefit of mammography for
improving stage at diagnosis (see later section on sensi-
tivity analysis).
Stage at Diagnosis without Mammography Fewer stu-
dies are available with stage distributions for African-
American women diagnosed without mammography.
Some of the studies combine in situ and Stage I diag-
noses as “early stage” and Stages II-IV as “advanced
stage.” One of these studies found 36% of women with
early stage disease and 64% with advanced stage disease
[76]. One study with a detailed stage distribution [74]
found the following distribution of stage at diagnosis:
In Situ - 4%; Stage I - 32%; Stage II - 43%; Stage III -
13%; Stage IV - 8%. This distribution is closely matched
to the Moorman et al [74] distribution of “early” vs.
“late,” so we used this second Bibb [74] stage distribution
as the estimate for women not receiving mammography.
Remission, Progressive Disease, or Recurrence, and
Deaths Due to Cancer Breast cancer can follow a com-
plex course of response to treatment, recurrence, remis-
sion, progression, and eventual death. To simplify the
potential sequence of events, the Markov model pre-
sumed that women with newly diagnosed cancer will be
treated, and the treatment will produce either a remis-
sion or progressive disease. In subsequent cycles,
women in remission are presumed to either stay in
remission or have recurrent illness. The probability of
staying in remission varied in the model as a function of
stage at initial diagnosis - remission continued for 98.5%
of women with Stage I disease but only continued for
67% of women with Stage IV disease. Remission either
continued or shifted to recurrent disease at each year of
the five-year model. Women who had a recurrence in
any one of the five years may have died in that year or
may have continued treatment with some probability of
a second remission.
Probabilities for all specific remission, treatment, or
recurrence branches were selected to match as closely
as possible the published five- and six-year survival rates
for African-American women with breast cancer, by
stage at diagnosis [73,77]. Annual death rates in the
model, by stage, were: Stage I - 0.75%; Stage II - 3%;
Stage III - 12.6%; Stage IV - 26.4%. To produce these
rates in years 2-5 of the model when women diagnosed
in previous years and having an initial remission can
experience recurrences and subsequent progressive dis-
ease, the probabilities of continued remission in each
subsequent year, by stage, were: Stage I - 97.5%; Stage II
- 94%; Stage III - 81%; Stage IV - 66%.
Deaths from Other Causes In all years of the model, a
probability of .01 was assigned to risk of death from
causes other than cancer [78,79].
Values for Health States
Mortality/Survival For mortality/survival analyses, all
states other than death were assigned a value of 1; death
was assigned a value of 0. Values were assigned at each
annual cycle of the model. Over five years, then, the
model calculates life expectancy on a scale from 0-5. If
all women died in beginning of the first year of the
model, the total life expectancy would be 0; if all
women survived for five years (even if many were being
treated for active cancer), the total life expectancy
would be 5.0.
Utilities For analysis of Quality-Adjusted Life Years, uti-
lities were assigned to each health state in which a
woman could start or end a year [Additional File 1:
Appendix Table 3] [80-86]. Different utility values were
assigned to women in remission from different stage of
cancer to reflect negative health impacts of breast
reconstruction surgery, adjuvant chemotherapy, long-
term effects of intensive chemotherapy, and other health
effects associated with treatment of more advanced
disease.
The simulation model software (TreeAge Pro, Tree-
Age Software) [87] allows for “transition states” that can
either add or subtract utility values during part of a year
even if individuals in the model do not end a model
cycle and start a new model cycle in that state. In our
model, “active treatment” was modeled in this way; sub-
tractions of .10, .20, and .25 were made from the utility
values for women who started the year in the well state
and had treatment for Stage I, Stage II, or Stages III or
IV cancer during that year.
Probability of Employment There were a relatively
small number of studies describing labor force participa-
tion among minority women with breast cancer. Not all
of these presented data separately by stage of disease or
presence of active treatment, so estimates for the model
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had to be made by combining parameters from different
studies. Our model presumed a cohort of women who
were all working full-time at the start of the simulation
to estimate a business case for eliminating disparities in
mammography from the employer, rather than societal,
perspective.
Bradley et al [88,89] reported a reduction in likelihood
of employment for women with cancer in the past two
years compared to women without cancer in the same
time period (54% vs. 64%). The difference was 6% in
women who had cancer three or more years prior to the
study date. Short et al [90] reported a similar 8%
decrease in the probability of working as a function of
having cancer; in addition, the relative probability of
working decreased as a function of stage at diagnosis.
More recently, Bradley et al [91] reported that among
women with breast cancer employed prior to diagnosis,
at least 12% appeared to move out of the labor force
altogether by retiring or becoming disabled. The effects
were stronger for those with more advanced stage can-
cers, while there was no employment effect on women
with in situ cancers. The non-employment effects of
breast cancer were about twice as strong for African-
American women.
Eversley [92] reported that African-American women
took eight more weeks off after surgery than white
women and that 44% of all women were not working at
three months after diagnosis. Satariano and DeLorenze
[93] reported that 60% of black women vs. 74% of white
women were back at work three months after diagnosis;
return to work also varied as a function of stage of dis-
ease at diagnosis, with 76% of women with “local” dis-
ease returning to work at three months, while 69% of
women with “regional” disease and 50% of women with
“remote” disease were back at work.
Only a few studies have examined absenteeism among
breast cancer survivors. Bradley et al [94] found that
women treated for breast cancer missed an average of
44.5 days from work and women with late stage disease
missed far more days from work than women with in
situ cancer.
We combined work loss hours estimates (Bradley et
al) with annual earnings (or wages) data (Bureau of
Labor Statistics) to calculate the monetary value of pro-
ductivity losses due to absenteeism for survivors who
are employed and in treatment.
II. Asthma Medications Model
Rates of Use of Appropriate Medications
Several published studies have shown racial/ethnic dis-
parities in the use of IHC or other preventive medica-
tions (e.g., cromolyn) for asthma [36,37,95]. The
relationship between some of these findings and the
HEDIS measure of appropriate asthma medications is
complicated because the HEDIS measure only requires a
single prescription to be filled during a year, and some
of the studies use regular ICS use as the key measure of
medication use. Rates of regular ICS use will inevitably
be lower than rates of having received at least one pre-
scription for preventive medications.
The NCQA State of Health Care report for 2008
shows a median rate of appropriate medication use
according to the HEDIS measure definition of approxi-
mately 92% across all three age groups for commercial
enrollees and 87% for Medicaid [35]. There is consider-
able variability in these rates from plan to plan [96].
These rates are for all plan members and are not strati-
fied by race/ethnicity.
Studies comparing medication use across racial/ethnic
groups report odds ratios of appropriate medication use
between .36 and .65 when comparing African-American
adults to a non-Hispanic white reference group [97,98].
The study by Ortega et al [36] found medication use
rates for African-American children and Hispanic chil-
dren at approximately half of the rate for non-Hispanic
white children; smaller disparities were reported for
children and adolescents in a Medicaid sample by Lieu
et al [95]. A more recent study by Smith et al [99]
found a 12% absolute disparity between black and white
children in a measure of underuse of controlled
medications.
The baseline scenario for the asthma model, then,
starts with a rate of appropriate medication use for min-
ority adults and children of 80% and posits a rate of
90% for non-Hispanic white children and adults. Elimi-
nation of the disparity involves raising the rate of medi-
cation use in minority adults and children to 90%.
Acute Exacerbations
Although there can be some asthma-related symptoms
and related lung function deficits on “normal” days,
most problems of lost work or school or need for medi-
cal care come as a result of acute exacerbations caused
by some environmental trigger. Some exacerbations are
severe enough to require an ER visit or hospital
admission.
Monthly probabilities of exacerbations leading to at
least one day off work or school were estimated from
studies using patient surveys to inquire about either
days off work or school or “physically unhealthy days”
in a given time period. In the three most directly rele-
vant studies, the monthly probabilities of at least one
day of work or school missed due to acute exacerbations
were .30 [95], .50 [98], and .37 [32]. We chose to use a
probability in the middle of this range: .40. These stu-
dies included patients with all levels of medication use.
To be consistent with the Sin et al report of a 50%
decrease in acute exacerbations through use of inhaled
corticosteroids [100,101], we used a monthly probability
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of acute exacerbations of .27 for those taking medica-
tions and .53 for those not taking medications.
Five recent studies included data on monthly probabil-
ities of ER or urgent care visits, with a range of prob-
abilities from .01 to .06 [49,95,98,102-104]. These
studies include patients of all severity levels and degrees
of compliance with medications. The ER visit rates for
patients with persistent asthma only (HEDIS denomina-
tor population) would be slightly higher. The probability
of an ER visit is higher for African-American or Hispa-
nic children and adults, with one study in a managed
care setting showing ER visit rates twice as high in
African-American patients as in non-Hispanic white
patients.
A recent review of clinical trials of inhaled corticoster-
oids and other preventive medications suggested that
use of these medications cut the rate of acute exacerba-
tions in half [101]. It is not clear exactly how to model
the effect of just barely meeting the HEDIS requirement
of one filled prescription in a year, but our “base case”
model presumes that most patients with asthma in a
HEDIS denominator population who receive a prescrip-
tion are taking medications as regularly as patients in
the studies reviewed. In sensitivity analyses, we model
the effects of a smaller benefit related to poorer levels of
adherence.
To maximize comparability of our results to those of
Paltiel et al [49], we chose to use rates from their
model, combining the probability of ER and urgent care
use. We multiplied those rates by two to estimate the
probability of ER/urgent care visits for African-Ameri-
can or Hispanic adults and children. The monthly prob-
abilities in the base model are .038 for patients using
medications and .076 for patients not using medications.
Monthly probabilities of hospital admission were also
derived from rates used by Paltiel et al [49], with adjust-
ment for the finding in several published studies of
higher hospitalization rates for African-American or
Hispanic patients with asthma. Monthly probabilities in
those studies ranged from .003 to .010. The ratio of
rates for patients using vs. not using medications were
also adjusted from those used by Paltiel et al [49] to
match the recent summary by Sin et al [101] showing a
decrease in hospitalization rates of approximately 50%
in patients using inhaled corticosteroids. Our base
model monthly probabilities for hospital admission were
.0035 for patients using medications and .0069 for
patients not using medications.
Days Missed from Work or School
For adults, we used 21.7 as the estimate of the number
of days per month potentially available for attendance at
work (2080 hours as a full-time work year = 260 days
per year = 21.67 days per month). For children and ado-
lescents, we used 15 as the estimate of the number of
days per month potentially available for attendance at
school (180 school days in a year = 15 days per month).
The 180 school days are actually not evenly distributed
across all 12 months of the year, so the effects of
exacerbations are clearly more important on lost school
days between September and June than they are in the
summer. However, we did not have any data that would
allow us to model seasonal variation in rates of exacer-
bation by race/ethnicity, so for purposes of creating a
base model we chose to model days off school as if
those days were distributed over an entire year. The
model will therefore underestimate the effect of exacer-
bations on lost school days for 9-10 months of the year
and overestimate the effect for 2-3 months, but the
average impact over the entire year should be reasonably
accurate.
The base model presumes that an average of four days
of work or school are lost per month among those
patients having acute exacerbations [32,95,98]. It pre-
sumes an additional day per month lost for those
patients requiring an ER or urgent care visit for an
exacerbation. It presumes an additional three days lost
for those patients requiring hospital admission for an
exacerbation. The number of days lost is not presumed
to vary for members of different racial/ethnic groups.
There are studies showing more “physically unhealthy
days” or days lost from work or school for African-
American or Hispanic patients with asthma [6], but we
are presuming that this is due to the higher probability
of exacerbations rather than a greater number of days
lost from work or school given an exacerbation.
QALYs
We used utility values from the Paltiel et al [49] model
to estimate the decrement in health status produced
by acute exacerbations, ER visits, and hospitalizations.
We also used their estimate of a .01 decrement in uti-
lity related to the use of medications. The utility value
assigned to a “normal” day without medications in the
model is .92; the value is .91 for a “normal” day with
medications. The utility value for a day with an exacer-
bation leading to being off from work or school is .72.
(We did not subtract the .01 for medication use on
these days, on the argument that the “disutility” of an
acute exacerbation would dominate any minor decre-
ment in health status due to side effects of medications
on those days.) We subtracted an additional .05 on
days in which an exacerbation required an ER visit,
and an additional .10 for days hospitalized. Utilities on
ER days, then, were .67 and on hospitalized days, .62.
In sensitivity analyses, the disutility of an ER visit or
hospitalization was increased to .10 and .20, respec-
tively. The utility values for a month in various
branches of the model were derived by multiplying the
utilities for each type of day by the number of days per
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month estimated for each of those states (see previous
section).
For patients in the model who died in a given month,
a utility of .92 or .91 (depending on medication use) was
assigned for 15 days and 0 for the remainder.
Deaths
We presumed that asthma-related deaths would only
occur among those patients experiencing exacerbations
requiring an ER visit or a hospital admission. The
probability of deaths in these groups was estimated at
.0002 for patients requiring ER visits and .0014 for
patients requiring hospitalization. Given the relatively
low probability of ER visits or admissions, the model’s
estimates for mortality in the entire denominator
population are reasonably consistent with those of
Suissa et al [29] and Paltiel et al [49]. The probability
of death from causes other than asthma was estimated
at .0001 per month.
Transition Probabilities
Patients are not consistent from month to month or
year to year in their use of medications. Although a rate
of adherence may be stable over time for a large popula-
tion, individuals can alternate between periods of use
and non-use, and the Markov model structure allows
for this factor to be included. We presumed that medi-
cation use would be generally stable from month to
month, but that some individuals taking medication and
experiencing no exacerbations in a given month would
not use medications in the following month (in various
versions of the model we used proportions of 5-10%).
Even some individuals experiencing ER visits or hospita-
lizations may not use medications in the following
month (perhaps believing them to be ineffective); we
estimated this proportion as 1%, with 99% of those
experiencing ER visits or hospitalizations continuing on
medications.
Among those not using medications in a given month,
we presumed that 1% of those not experiencing exacer-
bations would begin to use medications in the following
month, that 6% of those experiencing an exacerbation
would begin to use medications in the following month,
and that 25% of those requiring an ER visit or hospitali-
zation would begin using medications in the following
month.
In the absence of published data on these transitions
among minority group patients with asthma, some of
the transition probabilities are somewhat arbitrary. They
were adjusted, though, to produce the effect of gradually
rising use of medication for the group as a whole over
time. This trend of gradual increase is consistent with
national data on improvement in the HEDIS asthma
medication measure over time [96].
Additional material
Additional file 1: Appendix Tables. Three tables that accompany the
Appendix text.
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